CHF Solutions Initiates International Distribution with UK-Based APC Cardiovascular Ltd.
EDEN PRAIRIE, Minn., September 28, 2017 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (NASDAQ:CHFS) announced today that it is initiating international distribution of its products by entering into a distribution agreement with APC Cardiovascular Ltd, a distributor based in the United Kingdom. APC Cardiovascular will market CHF Solutions’ ® System and will serve as CHF Solutions authorized service provider in the United Kingdom.
“We are very pleased to expand our market reach in the UK with our new distributor partner, APC Cardiovascular, a premier cardiovascular and cardiology healthcare sales and distribution company,” said John Erb, CEO of CHF Solutions. “APC Cardiovascular has the market reach and service breadth to meet our expansion goals as we continue to execute our US and international growth plans. We have been in contact with healthcare providers that already own Aquadex FlexFlow consoles, and we look forward to APC Cardiovascular being able to service those units and bring them back into use,” Mr. Erb concluded.
About APC Cardiovascular Ltd.
Formed in 1989, APC Cardiovascular offers direct sales and support for numerous cardiovascular and cardiology product ranges, supplying hospitals, clinics and health-centres worldwide with a range of high quality products, incorporating the latest technological advances. From its head office in Hartford, Northwich, APC Cardiovascular’s national sales force provide full coverage to the UK market. APC Cardiovascular is committed to providing the medical profession with a range of quality products incorporating the latest technology and backed by the highest level of customer service and support.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding APC Cardiovascular servicing existing Aquadex FlexFlow consoles and bringing them back into use. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Claudia Napal Drayton Investor Relations:
Chief Financial Officer CHF Solutions, Inc.
CHF Solutions Inc. ir@chf-solutions.com
T: +1-952-345-4205
-or-
Bret Shapiro
Managing Partner
CORE IR
516 222 2560
brets@coreir.com
www.coreir.com
